Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HeartBeam (BEAT – Research Report) and Agios Pharma ...

Analysts Offer Insights on Healthcare Companies: HeartBeam (BEAT) and Agios Pharma (AGIO)

Agios Pharmaceuticals ($AGIO) announced an update on their ongoing clinical study. Study OverviewVIOLETA is a non-interventional study titled “Vora...

Vorasidenib’s Real-World Test in Germany: What Agios Investors Should Watch

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Analysts’ Top Healthcare Picks: Crinetics Pharmaceuticals (CRNX), Denali Therapeutics (DNLI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biodesix (BDSX – Research Report), Gilead Sciences...

Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Gilead Sciences (GILD) and Agios Pharma (AGIO)

The latest update is out from Agios Pharma ( ($AGIO) ). On January 12, 2026, Agios outlined its 2026 strategic priorities following the December 20...

Agios Pharma Sets 2026 Strategic Priorities After AQVESME Approval

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Agios Pharma, with a price target of $35.00. ...

Current Quarter	$-1.97	Next Quarter	$-1.82
Current Year	$-7.22	Next Year	$-6.77
QoQ Growth	+7.6%	YoY Growth	+6.2%
3Y EPS CAGR	-39.3%	Target Price	$36.75
Consensus	Buy	Upside	+32.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AGIO	$27.77	-1.38%	403.18K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AGIO	$27.77	-1.4%	403.18K
3
4
5
6

AGIO

AGIO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Agios Pharmaceuticals Inc. Data in Excel

Get Agios Pharmaceuticals Inc. Data in Excel